| General Information |
| Business: |
(Incorporated in Delaware)
We are a clinical stage biotech developing just one drug candidate, RTN-001, a daily pill for uncontrolled and resistant hypertension. We are evaluating RTN-001 in a Phase 2b trial that began in October 2025. We expect initial data in the first half of 2027.
Note: Net loss is for the 12 months that ended on June 30, 2026. The company has no product revenue, according to the prospectus.
(Note: Retension Pharmaceuticals priced its small IPO at $12.00 – the mid-point of its range – and upsized the IPO at pricing to 3.75 million shares – up from 3.3 million shares in the prospectus – to raise $45 million on Thursday night, Oct. 8, 2026. Background: Retension Pharmaceuticals filed its S-1/A on Oct. 5, 2026, and disclosed the terms for its IPO: 3.3 million shares at a price range of $11.00 to $13.00 to raise $39.6 million, if priced at the $12.00 mid-point of its range. Background: Retension Pharmaceuticals filed its S-1 for its IPO on Sept. 18, 2026, without disclosing the terms. Estimated proceeds were $60 million.)
|
| Industry: |
Pharmaceuticals |
| Employees: |
|
| Founded: |
2023 |
| Contact Information |
| Address |
1104 West Broad Street #1029 Falls Church, Virginia 22046 |
| Phone Number |
(703) 940-9761 |
| Web Address |
http://www.retensionpharmaceuticals.com/ |
| View Prospectus: |
Retension Pharmaceuticals |
| Financial Information |
| Market Cap |
$99.96mil |
| Revenues |
$0.0 mil (last 12 months) |
| Net Income |
$-11.94 mil (last 12 months) |
| IPO Profile |
| Symbol |
RTSN |
| Exchange |
NASDAQ |
| Shares (millions): |
3.8 |
| Price range |
$12.00 - $12.00 |
| Est. $ Volume |
$45.0 mil |
| Manager / Joint Managers |
Leerink Partners/Guggenheim Securities/Oppenheimer & Co./Titan Partners |
| CO-Managers |
|
| Expected To Trade: |
10/9/2026 |
|
Status:
|
Priced |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |